Transdermal lovastatin enhances fracture repair in rats

Journal of Bone and Mineral Research

Volumn 23, Issue 11, 2008, Pages 1722-1730

  Gutierrez, Gloria E ^a,b   Edwards, James R ^b   Garrett, Ian R ^a   Nyman, Jeffry S ^c   McCluskey, Brandon ^a   Rossini, Gianni ^a   Flores, Alda ^a   Neidre, Daria B ^d   Mundy, Gregory R ^b  

^a OsteoScreen   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c University of Texas at San Antonio   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Fracture; Fracture repair; HMG CoA reductase inhibitors; Orthopedics; Osteoporosis; Statins; Transdermal

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITOMETRY; BONE RADIOGRAPHY; BONE REMODELING; BONE STRENGTH; CALLUS; CELL NUCLEUS MEMBRANE; CONTROL GROUP; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; EXPERIMENTAL RAT; FEMALE; FRACTURE; FRACTURE HEALING; FRACTURE TREATMENT; HISTOLOGY; IMMUNOCYTOCHEMISTRY; LOW DRUG DOSE; MORPHOLOGY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; QUANTITATIVE ANALYSIS; RAT; RIGIDITY; TISSUE REPAIR;

ADMINISTRATION, CUTANEOUS; ANIMALS; BIOMECHANICS; BONE DENSITY; FEMALE; FEMORAL FRACTURES; FRACTURE HEALING; LOVASTATIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 54249137180     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080603     Document Type: Article

References (42)

1. Bax BE, Wozney JM, Ashhurst DE 1999 Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif Tissue Int 65:83-89.
2. Schmidmaier G, Wildemann B, Cromme F, Kandziora F, Haas NP, Raschke M 2002 Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: A biomechanical and histological study in rats. Bone 30:816-822.
3. Einhorn TA, Majeska RJ, Mohaideen A, Kagel EM, Bouxsein ML, Turek TJ, Wozney JM 2003 A single percutaneous injection of recombinant human bone morphogenetic protein-2 accelerates fracture repair. J Bone Joint Surg Am 85:1425-1435.
4. Hollinger JO, Leong K 1996 Poly(alpha-hydroxy acids): Carriers for bone morphogenetic proteins. Biomaterials 17:187-194.
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
6. Gutierrez G, Lalka D, Garrett I, Rossini G, Mundy G 2006 Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporos Int 17:1033-1042.
7. Garrett IR, Gutierrez GE, Rossini G, Nyman J, McCluskey B, Flores A, Mundy GR 2007 Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res 25:1351-1357.
8. Skoglund B, Aspenberg P 2007 Locally applied simvastatin improves fracture healing in mice. BMC Musculoskelet Disord 8:98-104.
9. Bonnarens F, Einhorn TA 1984 Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2:97-101.
10. Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA 2005 Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 20:1715-1722.
11. Iwaki A, Jingushi S, Oda Y, Izumi T, Shida JI, Tsuneyoshi M, Sugioka Y 1997 Localization and quantification of proliferating cells during rat fracture repair: Detection of proliferating cell nuclear antigen by immunohistochemistry. J Bone Miner Res 12:96-102.
12. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
13. Eckardt H, Christensen KS, Lind M, Hansen ES, Hall DWR, Hvid I 2005 Recombinant human bone morphogenetic protein 2 enhances bone healing in an experimental model of fractures at risk of non-union. Injury 36:489-494.
14. Radomsky ML, Aufdemorte TB, Swain LD, Fox WC, Spiro RC, Poser JW 1999 Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J Orthop Res 17:607-614.
15. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ 1985 Midazolam: Pharmacology and uses. Anesthesiology 62:310-324.
16. Love JN 1994 Beta-blocker toxicity: A clinical diagnosis. Am J Emerg Med 12:356-357.
17. Frost HM 1989 The biology of fracture healing. An overview for clinicians. Part II. Clin Orthop 248:294-309.
18. Frost HM 1989 The biology of fracture healing. An overview for clinicians. Part I. Clin Orthop 248:283-293.
19. Kloen P, Doty SB, Gordon E, Rubel IF, Goumans MJ, Helfet DL 2002 Expression and activation of the BMP-signaling components in human fracture nonunions. J Bone Joint Surg Am 84:1909-1918.
20. Kloen P, Di Paola M, Borens O, Richmond J, Perino G, Helfet DL, Goumans MJ 2003 BMP signaling components are expressed in human fracture callus. Bone 33:362-371.
21. Spector JA, Luchs JS, Mehrara BJ, Greenwald JA, Smith LP, Longaker MT 2001 Expression of bone morphogenetic proteins during membranous bone healing. Plast Reconstr Surg 107:124-134.
22. Cho TJ, Gerstenfeld LC, Einhorn TA 2002 Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res 17:513-520.
23. Bostrom MP 1998 Expression of bone morphogenetic proteins in fracture healing. Clin Orthop 355(Suppl):S116-S123.
24. Harris SEFJ, Harris MA, Ghosh-Choudhury N, Dallas MR, Wozney J, Mundy GR 1995 Recombinant bone morphogenetic protein 2 accelerates bone cell differentiation and stimulates BMP 2 mRNA expression and BMP 2 promoter activity in primary fetal rat calvarial osteoblast cultures. Mol Cell Differ 3:137-155.
25. Zhao M, Harris SE, Horn D, Geng Z, Nishimura R, Mundy GR, Chen D 2002 Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol 157:1049-1060.
26. Garrett IR, Gutierrez G, Mundy GR 2001 Statins and bone formation. Curr Pharm Des 7:715-736.
27. Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M, Huang P, MacIntyre I, Polak J 2001 Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol 158:247-257.
28. Edwards CJ, Hart DJ, Spector TD 2000 Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-2219.
29. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N 2004 Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92:458-471.
30. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S 2000 Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688-692.
31. Song C, Guo Z, Ma Q, Chen Z, Liu Z, Jia H, Dang G 2003 Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 308:458-462.
32. Hatano H, Maruo A, Bolander ME, Sarkar G 2003 Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 8:842-848.
33. Emmanuele L, Ortmann J, Doerflinger T, Traupe T, Barton M 2003 Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 302:67-72.
34. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R 2000 Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188.
35. Wang PS, Solomon DH, Mogun H, Avorn J 2000 HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216.
36. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H 2000 HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210.
37. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM 2005 Statin use and fracture risk: Study of a US veterans population. Arch Intern Med 165:2007-2012.
38. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HAP 2004 Use of statins and fracture: Results of 4 prospective studies and cumulative metaanalysis of observational studies and controlled trials. Arch Intern Med 164:146-152.
39. Wang JW, Xu SW, Yang DS, Lv RK 2007 Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int 18:1641-1650.
40. Fuentes I, Aguilera C 1998 Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase. Med Clin (Barc) 111:700-704.
41. Duell PB, Connor WE, Illingworth DR 1998 Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81:368-369.
42. Jacobson RH, Wang P, Glueck CJ 1997 Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 277:296-297.